, proteins located on the surface of different forms of Trypanosomatids are involved in metabolite exchange with the host. In particular, it has been characterised that T. cruzi possesses membrane proteins ecto-located, named ectoenzymes, whose main function is hydrolysis of extracellular nucleotides 9 . Ectoenzymes involve several enzyme families that have been discovered, cloned and functionally characterised. An important member of this family is ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase) enzyme that hydrolyses extracellular tri-and diphosphate nucleosides, such as ATP and ADP, which, in contrast to the established view, can be found in significant concentrations outside the cells 10 . It has been described that E-NTPDase is crucial for T. cruzi survival because it is involved in the acquisition and metabolism of the purine ring required for the parasite metabolism, without which it will not be able to synthesise new nucleotides 9, 11 . Experimental evidences suggest that the product of ATP hydrolysis by T. cruzi, E-NTPDase, mediates multiple effects in the host cell by interacting with type P2 purinergic receptors. Thus, the parasite acquires the potential to subvert and avoid host defence mechanisms and establish its parasitism and virulence 9, 10 . The present review aims to provide an overview of existing information about the mechanisms of purinergic signalling pathway activationbased on the activity of ecto-enzymes located on the surface of T. cruzi and the role of inhibitors of these enzymes in the clinical management of Chagas disease.
Abstract

Introduction
Chagas disease is a neglected tropical disease, which is distributed worldwide affecting about 12 million people in American countries. Over the years, several therapeutic targets have been investigated in vitro and in vivo in the attempt to develop a safe and efficient chemotherapy for this disease. However, despite countless efforts in this regard, the methods are still failing and new therapeutic targets represent an urgent reality. We believe that ecto-nucleoside triphosphate diphosphohydrolase, a crucial enzyme for Trypanosoma cruzi survival, is a good target. The present review aims to provide an overview about the activation mechanisms of purinergic signalling pathways based on the activity of ecto-enzymes located on T. cruzi surface and the role of inhibitors of these enzymes in the clinical management of Chagas disease.
Conclusion
The drug association mechanisms involving competitive antagonists of P2 receptors represent a good therapeutic strategy, inhibiting the essential processes for T. cruzi. Thus, the association between suramin and classical trypanocidal drugs is a promising tool in clinical management.
Introduction
Chagas disease is a neglected tropical disease that affects about 12 million people in American countries and, owing to migration, infected individuals are distributed worldwide 1, 2 . The disease is caused by an intracellular protozoan Trypanosoma cruzi, a hemoflagellate protozoan (family Trypanosomatidae, order Kinetoplastida), transmitted by triatomine insect (Triatoma, Panstrongylus, Rhodniusand). The parasite can also be acquired by blood transfusion, organ transplant, ingestion of food contaminated with triatomines or their faeces, or by congenital transmission 3 . The life cycle of T. cruzi involves mandatory passage through vertebrate (mammals, including man) and invertebrate (haematophagous triatomine insect) hosts in a series of stages 4 . Once the infection has been established in the vertebrate host, the parasite migrates to systemic organs such as liver, kidneys, spleen, bone marrow, intestine, pancreas and heart 5 . Although the parasite has the ability to infect many tissues and organs, it has intense tropism for the cardiac muscle. Thus, Chagas disease is characterised as the most common cause of non-ischemic cardiomyopathy worldwide, leading to the death of thousands of patients every year, mainly due to dilated cardiomyopathy, congestive heart failure, arrhythmias and thromboembolic events that occur in approximately 30% of infected individuals 6 . A relevant therapeutic strategy in the management of Chagas disease has been based, in the last decade, on the parasite biology Competing interests: none declared. Conflict of interests: none declared.
All authors contributed to conception and design, manuscript preparation, read and approved the final manuscript. All authors abide by the Association for Medical Ethics (AME) ethical rules of disclosure.
that can be induced by pathogen infection. This way it is able to trigger cellular events such as proliferation, differentiation, chemotaxis, release of cytokines or lysosomal constituents, and generation of reactive oxygen or nitrogen species. All those mediators are highly toxic to T. cruzi 18 . It has been described that Tc-ENTPDase-1 might play a modulatory role in response to these toxic mediators and in consequence affect purine recovery pathways, which are necessary for nutrition and to maintain parasite viability; beyond this, they can be involved in inflammatory processes, modulation of the host immune system and consequently increase the virulence mechanisms of T. cruzi 17, 19, 20 . A virulence key mechanism related to Tc-ENTPDase-1 presents a relation with enzyme capacity that interferes with extracellular ATP signals and interrupts purinergic signalling, limiting mechanisms of host defences. This activity seems to be dependent on the presence of divalent cations such as calcium and magnesium 17, 19 . The main consequence of extracellular ATP hydrolysis by T. cruzi catalysed by Tc-ENTPDase-1 is purine recovery from their hosts 16 . Purines represent precursor molecules fundamental for DNA and RNA synthesis, which are carriers of high-energy phosphate bonds, constituents of coenzymes and modulators of certain enzymatic reactions 21 . This makes the parasite to develop an absolute need for purines once T. cruzi does not have the machinery to synthesise its own purine ring de novo 19 . The inability of T. cruzi to produce nucleobases (adenine, guanine, xanthine, hypoxanthine) and nucleosides (adenosine, guanosine and inosine) makes this parasite to transport these compounds across its plasma membrane. This way initiates the acquisition of the purine ring and therefore nutrients 21 . There are strong evidences indicating the presence of specific transporters, receptors coupled to the G i subunit of G protein, which can be inhibited by adenylyl cyclase and regulate ion channels 13, 15 . In general, P2Y receptors can be activated by ATP, ADP, UTP, UDP, ITP, and nucleotide sugars, albeit agonist specificity varies between subtypes and different animal species 11 . It has been reported that a variety of pathogens are capable of synthesising ectonucleotidases that hydrolyse extracellular NTPs and NDPs, activating purinergic receptors. This activation begins a series of biological responses in the microenvironment of the infected organism, which can favour the survival and replication mechanisms of the parasite 7 . An important ectonucleotidase described in trypanosomatids, which activates purinergic receptors, is the ectonucleoside triphosphate diphosphohydrolases (E-NTPDases) member of the CD39 family. These enzymes are characterised by the presence of five 'apyrase conserved regions' (ACR1 to ACR5) 9 .
There is strong evidence that the parasite-associated E-NTPDases imply in the biological responses 16 . In general, these responses contribute to enhance cell adhesion mechanisms, intracellular survival, and modulation of host immunity system, and consequently enhance the virulence mechanisms of the parasite.
Implication of T. Cruzi E-NTPDase for purines acquisition
NTPDase enzymatic activity has been described for several protozoan parasites, especially trypanosomatids. At the moment, just one ectonucleotidase has been discovered for T. cruzi. This was named Tc-ENTPDase-1, a homologue to CD39 family enzymes, characterised as an important virulence biomolecule located on the parasite surface, capable of hydrolysing extracellular NTPs and NDPs, especially extracellular ATP 17 .
It is known that the extracellular ATP represents a danger signal
Discussion
Activation of purinergic receptors by pathogens Until 1970s, it was believed that extracellular diphosphate (NDPs) and triphosphate (NTPs) nucleosides were generated by the process of cellular damage, and no biological function was assigned to them. Currently, it is known that these molecules represent key messengers that mediate diverse biological processes through the activation of the receptosome, specifically purinergic receptors
The extracellular nucleotides are involved in an array of cell-specific responses, but the integrative view of purinergic signalling as a multistep coordinated cascade has emerged recently 12 .
Activation of the purinergic signalling pathway involves two types of specific receptors distributed in the body [the families of type 1 (P1) and type 2 (P2) purinergic receptors] 13 . According to molecular, biochemical, and pharmacological evidence, Adenosine/P1 receptors have been further subdivided into four subtypes: A1, A2A, A2B, and A3; all couple to G proteins and adenosine is the main activator of these receptors.
The P2 receptors are divided into two families: P2X and P2Y receptors 12 . Based on differences in molecular structure and signal transduction mechanisms, P2X receptors consist of a trimeric ligand-gated ion channel, and there are seven subunits of the P2X numbered P2X 1 through P2X 7 , which involve heterotrimers and homotrimers. These receptors respond to several extracellular mono-and dinucleotides, but are activated principally by ATP 14 . The P2Y receptors, in general, are G protein-coupled and they are categorised into two subfamilies. The first includes P2Y 1 , P2Y 2 , P2Y 4 , P2Y 6 and P2Y 11 receptors that are predominantly coupled to the subunit Gq of the G protein, and both are activated by phospholipase C-β. The second involves P2Y 12 , P2Y 13 , and P2Y 14 Licensee Competing interests: none declared. Conflict of interests: none declared.
All authors contributed to conception and design, manuscript preparation, read and approved the final manuscript. All authors abide by the Association for Medical Ethics (AME) ethical rules of disclosure.
advances in understanding the molecular processes between transporters and parasites, further investigations are still needed for a complete explanation, especially in T. cruzi 23 .
Suramin, a potential strategy for Tc-NTPDase inhibition Evident therapeutic implications have been directed in parasitology, especially in relation to purine recovery pathways and activity of specific T. cruzi transporters 7 . It has been described that drugs capable of acting on the biology of T. cruzi represent a promising tool to reduce the infectivity by inhibiting evasion mechanisms used by the parasite to escape the immune system 23 . Trypanocidal drugs that are able to influence the biochemical activity of purinergic receptors, acting like competitive antagonists of P2X and P2Y receptors, may be promising in the clinical management of Chagas disease 24 . It has been shown that there is a strong correlation of ecto-ATPase activity inhibition with reduced capacity of adhesion and internalisation of T. cruzi in the host cell 17, 20 . An important ecto-ATPase inhibitor, capable of interfering with purinergic receptors and consequently in the biology of T. cruzi, is suramin, a polysulphonated naphthylurea compound, derivative of urea, that functions as a competitive antagonist of P2 receptors, used for the prophylactic treatment of African tripassonomiase 25 . After decades of clinical studies with suramin, it was proved that it reduces the activity of enzymes such as retroviruses (reverse transcriptase, protein kinase C, DNA polymerase, protein tyrosine phosphatase and Mg 2+ ATPase) 16, 25 . It has been reported that in T. cruzi, suramin can inhibit various enzymes, the endocytosis of some molecules, and interfere with the process of cell division 25 . Bisaggio et al. 26 showed modulatory effect of suramin on enzymatic activity of the ecto-ATPase Mg 2+ dependent on the surface of T. cruzi. This inhibition was dose-dependent, and an important biological consequence reported is the accentuated reduction of the ATP hydrolysis rate and a significant reduction in the electrondense reaction product observed on the cell surface of epimastigote and trypomastigote forms of the parasite. Moreover, the drug inhibits the growth of epimastigote forms without affecting their cell viability or metacyclogenesis rate. Although these authors pointed the involvement of suramin on biological mechanisms related to Tc-NTPDase inhibition, due to binding to P2 receptors, this activity has been demonstrated only in vitro. Relative ineffectiveness of suramin has been demonstrated in studies in vivo and there are urgent necessities of controlled preclinical and clinical studies to define the molecular mechanisms involved in the modulation of parasite biology 19, 20 . Thus, we considered suramin and purinergic signalling inhibition as a promising target in the clinical management of Chagas disease. However, it is worth mentioning the relevance of nucleoside and nucleobase transporters used by T. cruzi and are also associated with the plasma membrane of the parasite, that are configured to accommodate a repertoire of nucleosides by the parasite, essential for its metabolism and survival 22 .
In general, specific nucleobase transporters have been considered as an important pharmacological target and have been extensively studied, especially in Trypanosomatidae. Applications of molecular and genetic approaches have allowed the identification and functional characterisation of a cohort of transporters and activation of the associated genes in these parasites 23 . However, molecular investigations to specify the transporter associations to T. cruzi are still required 22 . Some important transporters that act in trypanosomatids, especially T. cruzi, T. brucei and Leishmania spp., presenting specificity substrates had been investigated and can serve as starting points for more extensive reading (Table 1) .
Till date, it is known that these receptors are essential for nutrient acquisition and to increase T. cruzi virulence. A number of studies have been developed to demonstrate the presence and to define the specificity of purine transporters. However, despite Dean et al.
36
T. brucei Carboxylates PAD1, PAD2
Montalvetti et al.
37
T. cruzi Water, glycerol and osmolytes TcAQP1 strongly associated with the mechanisms of virulence of the parasite.
Conclusion
Chagas disease is a reality worldwide and a challenge to the health sector.
